The European Commission announced Monday that it will decide by January 14 whether to approve Swiss pharmaceutical conglomerate Novartis’s plans to merge with UK rival GlaxoSmithKline.
Novartis is set to acquire Glaxo’s oncology product unit in a $14.5 billion acquisition; an additional $1.5 billion would be paid pending results of an ongoing melanoma treatment trial, reports say.
Glaxo, meanwhile, would acquire Novartis’s vaccines operations, without the flu vaccine, for $5.25 billion, as well as potential royalties and milestone payments of up to $1.8 billion.
The Commission is investigating the terms of the transaction and will rule next month on the deal. The announcement comes days after the Commission approved of medical device maker Medtronic’s acquisition of Covidien for $43 billion, though regulators implemented concessions on the deal.
Full content: Today Online
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Hess Shareholders Approve $53 Billion Merger with Chevron
May 28, 2024 by
CPI
EU Regulators Engage with Telegram as App Nears Critical Usage Threshold
May 28, 2024 by
CPI
EEX Offers Remedies to Address EU Antitrust Concerns Over Nasdaq Deal
May 28, 2024 by
CPI
BRG Expands European Competition Practice with New Expert Team in Brussels
May 28, 2024 by
CPI
UK Law Empowers Regulators to Fine Big Tech Without Court Approval
May 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI